Fat slows gastric emptying on its own
Several active research areas include: Metabolic dysfunction-associated steatotic liver disease (MASLD) : Multiple trials are evaluating semaglutide's effects on liver fat content and biomarkers, with preliminary data suggesting potential benefits in reducing hepatic steatosis and improving liver enzyme profiles Chronic kidney disease : Studies examining renal outcomes in patients with type 2 diabetes and established kidney disease, building on secondary analyses from SUSTAIN 6 showing reduced progression of diabetic nephropathy Obstructive sleep apnea : Ongoing trials investigating whether weight loss achieved with semaglutide improves sleep apnea severity and related cardiovascular outcomes Addiction and substance use disorders : Early-phase research exploring GLP-1 receptor agonists' potential effects on reward pathways and addictive behaviors, though this remains highly preliminary Alzheimer's disease and cognitive function : Preclinical evidence suggesting neuroprotective properties has prompted clinical trials examining cognitive outcomes in at-risk populations Researchers are also investigating combination therapies , such as cagrilintide plus semaglutide (CagriSema), which is currently under development
Not affiliated: PlexusDx is independent of GoodLife and has no commercial relationship with the companies reviewed here
With the appetite-suppressing effects of Semaglutide, you may find that your regular eating habits change dramatically, which can lead to feelings of discomfort or even loss of control around food
Specifically, semaglutide should be avoided or approached cautiously in the following cases : Medullary Thyroid Carcinoma (MTC) or MEN 2 : Individuals with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should avoid semaglutide
Others prefer Tirzepatide because it provides stronger appetite suppression and faster visible results
